[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ECSP077397A - Preparación y uso de derivados de ácido bifenil-4-il-carbonilamino para el tratamiento de obesidad - Google Patents

Preparación y uso de derivados de ácido bifenil-4-il-carbonilamino para el tratamiento de obesidad

Info

Publication number
ECSP077397A
ECSP077397A EC2007007397A ECSP077397A ECSP077397A EC SP077397 A ECSP077397 A EC SP077397A EC 2007007397 A EC2007007397 A EC 2007007397A EC SP077397 A ECSP077397 A EC SP077397A EC SP077397 A ECSP077397 A EC SP077397A
Authority
EC
Ecuador
Prior art keywords
carbonilamine
bifenil
preparation
acid derivatives
obesity treatment
Prior art date
Application number
EC2007007397A
Other languages
English (en)
Inventor
Derek B Lowe
Tatiana E Shelekhin
Roger A Smith
Ann-Marie Campbell
Philip Coish
Stephen O'connor
Roger B Clark
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of ECSP077397A publication Critical patent/ECSP077397A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta invención se refiere a ciertos compuestos de ácido bifenil-4-il carbonilamino, composiciones y métodos para tratar o prevenir obesidad y enfermedades relacionadas.
EC2007007397A 2004-10-15 2007-04-13 Preparación y uso de derivados de ácido bifenil-4-il-carbonilamino para el tratamiento de obesidad ECSP077397A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61897504P 2004-10-15 2004-10-15

Publications (1)

Publication Number Publication Date
ECSP077397A true ECSP077397A (es) 2007-05-30

Family

ID=36203612

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007397A ECSP077397A (es) 2004-10-15 2007-04-13 Preparación y uso de derivados de ácido bifenil-4-il-carbonilamino para el tratamiento de obesidad

Country Status (21)

Country Link
US (2) US7759376B2 (es)
EP (1) EP1805156B1 (es)
JP (1) JP2008516978A (es)
KR (1) KR20070063546A (es)
CN (1) CN101087769A (es)
AT (1) ATE492542T1 (es)
AU (1) AU2005295453A1 (es)
BR (1) BRPI0516483A (es)
CA (1) CA2583784A1 (es)
CR (1) CR9034A (es)
DE (1) DE602005025517D1 (es)
EA (1) EA200700851A1 (es)
EC (1) ECSP077397A (es)
ES (1) ES2357015T3 (es)
IL (1) IL182218A0 (es)
MA (1) MA28935B1 (es)
MX (1) MX2007004217A (es)
NO (1) NO20072461L (es)
TN (1) TNSN07111A1 (es)
WO (1) WO2006044775A2 (es)
ZA (1) ZA200703002B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008523133A (ja) 2004-12-14 2008-07-03 アストラゼネカ アクチボラグ Ｄｇａｔ阻害剤としてのオキサジアゾール誘導体
CA2630463C (en) 2005-11-21 2015-01-06 Anadys Pharmaceuticals, Inc. Novel process for the preparation of 5-amino-3h-thiazolo[4,5-d]pyrimidin-2-one
US7749997B2 (en) 2005-12-22 2010-07-06 Astrazeneca Ab Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors
ATE529405T1 (de) 2006-03-31 2011-11-15 Novartis Ag (4-(4-ä6-(trifluoromethyl-pyridin-3-ylamino)-n- enthaltend-heteroarylü-phenyl)-cyclohexyl)- essigsäure-derivate und ihre pharmazeutische anwendungen
JP2009538892A (ja) 2006-05-30 2009-11-12 アストラゼネカ アクチボラグ アセチル補酵素ａジアシルグリセロールアシルトランスフェラーゼの阻害薬としての置換５−フェニルアミノ−１，３，４−オキサジアゾール−２−イルカルボニルアミノ−４−フェノキシ−シクロヘキサンカルボン酸
CA2651663A1 (en) 2006-05-30 2007-12-06 Astrazeneca Ab Chemical compounds
KR100795462B1 (ko) 2006-09-27 2008-01-16 한국생명공학연구원 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물
KR100811100B1 (ko) 2006-09-27 2008-03-06 한국생명공학연구원 벤즈아졸 유도체를 유효성분으로 함유하는 대사성 질환예방 및 치료용 약학적 조성물
AR063311A1 (es) * 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
WO2008073865A2 (en) * 2006-12-11 2008-06-19 Novartis Ag Method of preventing or treating myocardial ischemia
CL2008001671A1 (es) 2007-06-08 2009-07-17 Janssen Pharmaceutica Nv Compuestos derivados de piperidina/piperazina inhibidores de dgat1, composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades metabolicas especialmente diabetes.
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
US8633197B2 (en) 2007-06-08 2014-01-21 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JP5443342B2 (ja) 2007-06-08 2014-03-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピペリジン／ピペラジン誘導体
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
PE20091682A1 (es) 2007-12-20 2009-12-04 Astrazeneca Ab Compuestos de carbamoilo como inhibidores de dgat1 190
WO2009135590A1 (en) 2008-05-05 2009-11-12 Sanofi-Aventis Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
JP5579170B2 (ja) 2008-06-05 2014-08-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｄｇａｔ阻害剤とｐｐａｒ作動薬を含有する薬剤組み合わせ物
UY32349A (es) * 2008-12-23 2010-07-30 Novartis Ag Derivados de biaril-bencil-amina
CA2749700A1 (en) * 2009-01-23 2010-07-29 Msd K.K. Benzodiazepin-2-on derivatives
EP3366686B9 (en) 2009-03-20 2021-08-04 Metabasis Therapeutics, Inc. Inhibitors of diacylglycerol o-acyltransferase 1 (dgat-1) and uses thereof
US8268820B2 (en) * 2009-03-26 2012-09-18 Hoffmann-La Roche Inc. 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds
AU2010229653A1 (en) 2009-03-27 2011-10-20 Astrazeneca Ab Methods for preventing major adverse cardiovascular events with DPP-IV inhibitors
TW201103895A (en) 2009-06-19 2011-02-01 Astrazeneca Ab Chemical compounds
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
RU2012149806A (ru) 2009-11-05 2014-05-27 Пирамал Энтерпрайзис Лимитед Карбоксиоксазольные или тиазольные соединения в качестве ингибиторов dgat-1, пригодные для лечения ожирения
SG181702A1 (en) * 2009-12-16 2012-07-30 Pola Chem Ind Inc Preventing or ameliorating agent for pigmentation
EP2552441B1 (en) 2010-03-30 2016-05-04 Novartis AG Uses of dgat1 inhibitors
WO2012150784A2 (ko) 2011-05-03 2012-11-08 한국생명공학연구원 신규한 인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9499482B2 (en) 2012-09-05 2016-11-22 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
WO2014039411A1 (en) 2012-09-05 2014-03-13 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
CN106795155B (zh) * 2014-08-01 2023-06-16 拜耳医药股份有限公司 一种化合物的制备方法及其纯化以用作活性药物成分
CN105646510A (zh) * 2014-12-02 2016-06-08 重庆宁牧生态农业有限公司 一种用作抗肥胖剂的化合物
SG11202008971VA (en) 2018-03-16 2020-10-29 Anji Pharmaceuticals Inc Compositions and methods for treating severe constipation
WO2020252353A1 (en) * 2019-06-12 2020-12-17 Vanderbilt University Amino acid transport inhibitors and the uses thereof
CN112336718A (zh) * 2020-10-19 2021-02-09 济南大学 一种苯并咪唑衍生物作为α-葡萄糖苷酶抑制剂及其应用
WO2023085931A1 (en) 2021-11-11 2023-05-19 Koninklijke Nederlandse Akademie Van Wetenschappen Hepatic organoids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4164645B2 (ja) * 2002-08-09 2008-10-15 株式会社大塚製薬工場 Ｄｇａｔ阻害剤
NZ539952A (en) * 2002-11-22 2008-05-30 Japan Tobacco Inc Fused bicyclic nitrogen-containing heterocyclic compounds for treating diabetes, obesity and syndrome X
AR044152A1 (es) * 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad

Also Published As

Publication number Publication date
EP1805156B1 (en) 2010-12-22
WO2006044775A2 (en) 2006-04-27
AU2005295453A1 (en) 2006-04-27
US7759376B2 (en) 2010-07-20
TNSN07111A1 (en) 2008-06-02
ES2357015T3 (es) 2011-04-15
CN101087769A (zh) 2007-12-12
EA200700851A1 (ru) 2007-12-28
KR20070063546A (ko) 2007-06-19
MX2007004217A (es) 2007-06-11
IL182218A0 (en) 2007-09-20
JP2008516978A (ja) 2008-05-22
ZA200703002B (en) 2008-08-27
NO20072461L (no) 2007-07-03
EP1805156A4 (en) 2009-06-10
EP1805156A2 (en) 2007-07-11
CA2583784A1 (en) 2006-04-27
US20070265298A1 (en) 2007-11-15
WO2006044775A3 (en) 2006-06-15
US20110118302A1 (en) 2011-05-19
BRPI0516483A (pt) 2008-09-02
CR9034A (es) 2008-11-18
MA28935B1 (fr) 2007-10-01
ATE492542T1 (de) 2011-01-15
DE602005025517D1 (de) 2011-02-03

Similar Documents

Publication Publication Date Title
ECSP077397A (es) Preparación y uso de derivados de ácido bifenil-4-il-carbonilamino para el tratamiento de obesidad
UY28314A1 (es) Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad
WO2007016538A3 (en) Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
ECSP088561A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
WO2006113919A3 (en) Aryl alkyl acid derivatives for and use thereof
PA8640701A1 (es) Indazoles utiles para tratamiento de enfermedades cardiovascular
ECSP088749A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
ECSP066883A (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes
UY28734A1 (es) Compuestos de quinolina sustituidos
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
ECSP045156A (es) Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6
UY29161A1 (es) Nuevos heterociclos
ECSP067096A (es) Metabolitos de indolilalquilamina como ligandos 5-hidroxitriptamina-6
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
ECSP078015A (es) 4-anilino-3-quinolinocarbonitrilos para el tratamiento de cáncer
DOP2004000900A (es) Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad
DOP2003000749A (es) Derivados de indolil pirazinona utile para el tratamiento de trastornos hiperproliferativos
CU20080120A7 (es) Derivados de pirimidinil aril urea e inhibidores fgf
DOP2005000015A (es) Compuestos de quinolina sustituidos